Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System

This study has been completed.
Sponsor:
Information provided by:
Abbott Vascular
ClinicalTrials.gov Identifier:
NCT00180453
First received: September 13, 2005
Last updated: January 5, 2010
Last verified: June 2009
  Purpose

Prospective, randomized, controlled, single-blinded, parallel two-arm, multicenter trial.

Test arm: XIENCE V® Everolimus Eluting Coronary Stent System(stent length: 18mm, diameter: 3.0mm) Control arm: Metallic stent (MULTI-LINK VISION® metallic stent(stent length: 18mm, diameter: 3.0mm) Follow-up angiographic imaging and intra vascular ultra sound (IVUS) at 180 days and 1 year


Condition Intervention Phase
Coronary Artery Disease
Everolimus
Vascular Disease
Myocardial Ischemia
Coronary Artery Stenosis
Device: Coronary artery drug eluting stent placement
Device: Coronary artery stent placement
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: SPIRIT First: A Clinical Evaluation of an Investigational Device. The Abbott XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions

Resource links provided by NLM:


Further study details as provided by Abbott Vascular:

Primary Outcome Measures:
  • In-stent late loss [ Time Frame: at 180 days post procedure ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • In-stent late loss [ Time Frame: at 1 year post procedure ] [ Designated as safety issue: Yes ]
  • In-segment Late Loss [ Time Frame: at 180 days and 1 year ] [ Designated as safety issue: Yes ]
  • In-stent and in-segment %Volume Obstruction [ Time Frame: at 180 days and 1 year ] [ Designated as safety issue: Yes ]
  • In-stent and in-segment %Diameter Stenosis [ Time Frame: at 180 days and 1 year ] [ Designated as safety issue: Yes ]
  • In-stent and in-segment Angiographic Binary Restenosis rate [ Time Frame: at 180 days and 1 year ] [ Designated as safety issue: Yes ]
  • Persisting incomplete apposition, late incomplete apposition, aneurysm, thrombus, persisting dissection [ Time Frame: at 180 days and 1 year ] [ Designated as safety issue: Yes ]
  • Major Adverse Cardiac Events [ Time Frame: at 30, 180, 270 days, and 1, 2, 3, 4, 5 years ] [ Designated as safety issue: Yes ]
  • Target Vessel Failure [ Time Frame: at 30, 180, 270 days, and 1, 2, 3, 4, 5 years ] [ Designated as safety issue: Yes ]
  • Acute success (device, procedure and clinical) [ Time Frame: Acute ] [ Designated as safety issue: Yes ]

Enrollment: 60
Study Start Date: December 2003
Study Completion Date: June 2009
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
Device: Coronary artery drug eluting stent placement
Coronary artery drug eluting stent placement
Active Comparator: 2
Abbott Vascular MULTI-LINK VISION® BMS
Device: Coronary artery stent placement
Coronary artery stent placement
Other Name: Abbott Vascular MULTI-LINK VISION® coronary stent system

Detailed Description:

The SPIRIT FIRST clinical trial will enroll approximately 60 patients and will assess the feasibility and performance of the XIENCE V® Everolimus Eluting Coronary Stent System in the treatment of patients with de novo native coronary artery lesions. In this trial, the XIENCE V® Everolimus Eluting Coronary Stent System will be compared to the MULTI-LINK VISION® metallic stent which is CE marked and FDA approved and is available for commercial use in Europe and in the United States. The SPIRIT FIRST Clinical trial will enroll approximately 60 patients (30 patients in the test arm and 30 patients in the control arm) with de novo native coronary artery lesions in 4 clinical sites in The Netherlands and Germany

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Patient must be at least 18 years of age.
  2. Patient is able to verbally acknowledge an understanding of the associated risks, benefits and treatment alternatives of receiving the XIENCE™ V Everolimus Eluting Coronary Stent System and his or her legally authorized representative provides written informed consent prior to the stent procedure, as approved by the appropriate Ethics Committee.
  3. Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study).
  4. Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.
  5. Patient must agree to undergo all protocol-required follow-up examinations including angiographic and IVUS follow-up at two time points (180 days and 1 year ).
  6. Female patients of childbearing potential must have had a negative pregnancy test within 7 days before treatment, and must not be nursing at the time of treatment.
  7. Female patients of childbearing potential must also agree at time of consent to use birth control up to and including the second angiographic follow-up at 1 year.

Inclusion Criteria: Angiographic

  1. Planned single, de novo, type A - B1, native coronary artery lesion treatment.
  2. Target lesion must be located in a native vessel with a diameter of 3.0 mm assessed by QCA on-line.
  3. Target lesion length ≤ 12 mm, assessed by QCA on-line.
  4. The target lesion must be in a major artery or branch with a stenosis of ≥ 50% and < 100% assessed by QCA on-line and with a TIMI flow of ≥ 1.

Exclusion Criteria

  1. Patient has had a known acute myocardial infarction (greater than two times the upper limit of normal CK with presence of CK-MB) within 3 days preceding the index procedure and CK has not returned to normal limits at the time of the procedure.
  2. Patient has current or a history of unstable arrhythmias, regardless of whether cardiac rhythm management devices are used (e.g., pacemaker, Automatic Implantable Cardioverter Defibrillator).
  3. Patient has a known left ventricular ejection fraction ≥ 30%.
  4. Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant.
  5. Patient is receiving or scheduled to receive chemotherapy or radiation therapy within 30 days prior to or after the procedure.
  6. Patient is receiving immunosuppression therapy or has known immunosuppressive disease.
  7. Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin).
  8. Patient has a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, cobalt, chromium, nickel, tungsten, everolimus, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated.
  9. Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis).
  10. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL, patient on dialysis).
  11. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  12. Patient has had a cerebrovascular accident (CVA) or stroke or transient ischemic neurological attack (TIA) within the past six months.
  13. Patient has had a significant GI or urinary bleed within the past six months.
  14. Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion or extreme anticoagulation.
  15. Patient has other medical illness (e.g., cancer or congestive heart failure) or recent history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year).
  16. Patient is already participating in another investigational use device or drug study or has completed the follow-up phase of another trial within the last 30 days.
  17. Patient has received a drug eluting stent within the last 1 year.

Exclusion Criteria: Angiographic

  1. The target lesion meets any of the following criteria:

    1. Aorto-ostial location
    2. Unprotected left main location
    3. Located within 2 mm of the origin of the LAD or LCX
    4. Located within or distal to an arterial or saphenous vein graft
    5. Located within 2 mm of a bifurcation
    6. Located distal to a previously implanted stent (same major epicardial vessel)
    7. Located in a major epicardial vessel that has been previously treated with brachytherapy
    8. Located in a major epicardial vessel that has been previously treated with any type of PCI (e.g., POBA, stent, cutting balloon, atherectomy), except if previous treatment occurred in a side branch distal to target lesion at least 180 days preceding the index procedure
    9. Involves jailing of side branches > 2.0 mm in diameter
    10. Total occlusion (TIMI flow 0)
    11. Excessive tortuosity proximal to or within the lesion
    12. Extreme angulation (≥ 90%) proximal to or within the lesion
    13. Moderate to heavy calcification
    14. Restenotic from previous intervention
  2. The target vessel contains thrombus.
  3. Another significant lesion (≥ 40 %DS) is located in the same major epicardial vessel as the target lesion.
  4. Patient has a high probability that a procedure other than pre-dilatation and stenting will be required for treatment of the target vessel (e.g. atherectomy, cutting balloon).
  5. Patient has additional lesion(s) for which an intervention within 180 days (prior to or after) of the index procedure would be required or has been performed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180453

Locations
Denmark
Skejby Sygehus
Aarhus, Denmark
Germany
Herzzentrum Bad Krozingen
Bad Krozingen, Germany, 79189
Kerckhoff-Klinik
Bad Nauheim, Germany, 61231
Herzzentrum Bad Oeynhausen
Bad Oeynhausen, Germany, 32545
Herzzentrum Siegburg GmbH
Siegburg, Germany
Netherlands
Academisch Medisch Centrum
Amsterdam, Netherlands, 1105 AZ
Erasmus Medical Center
Rotterdam, Netherlands
Sponsors and Collaborators
Abbott Vascular
Investigators
Principal Investigator: Patrick Serruys, MD Erasmus Medical Center
  More Information

Additional Information:
Publications:
Popma, J. J. and Tulli, M. Spirit First- Another Hurdle is Cleared. EuroIntervention,Vol.1: 260-263, 2005
Serruys, P.W.,.Ong, A.T.,Piek, J.J, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention, Vol. 1: 58-65, 2005
Tsuchida, K.,Piek, J.J., Neumann, F.J., et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial). EuroIntervention 1; 266-272, 2005
Beijk, M.A., Neumann, F.J.,Wiemer, M., et al. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial. EuroIntervention :1;266-272,2007

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Matt Kiely, Abbott Vascular
ClinicalTrials.gov Identifier: NCT00180453     History of Changes
Other Study ID Numbers: 02-350
Study First Received: September 13, 2005
Last Updated: January 5, 2010
Health Authority: Netherlands: Dutch Health Care Inspectorate

Keywords provided by Abbott Vascular:
Cardiovascular disease
Ischemia

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Coronary Stenosis
Ischemia
Myocardial Ischemia
Vascular Diseases
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Everolimus
Sirolimus
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014